NASDAQ:OCGN Ocugen Q3 2025 Earnings Report $1.61 +0.08 (+5.23%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$1.62 +0.01 (+0.62%) As of 10/24/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Ocugen EPS ResultsActual EPSN/AConsensus EPS -$0.06Beat/MissN/AOne Year Ago EPSN/AOcugen Revenue ResultsActual RevenueN/AExpected Revenue$0.44 millionBeat/MissN/AYoY Revenue GrowthN/AOcugen Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time8:30AM ETConference Call ResourcesEarnings HistoryCompany Profile Ocugen Earnings HeadlinesOcugen, Inc. Scheduled to Host Conference Call for Third Quarter 2025 Financial Results on November 5, 2025October 23 at 7:50 AM | quiverquant.comQOcugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial ResultsOctober 23 at 7:30 AM | globenewswire.comMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff, as the world's biggest car firm prepares to launch a "mind blowing" new product. It has nothing to do with EVs, or self-driving cars. In fact, it's not a car at all... | Altimetry (Ad)Ocugen to Highlight Gene Therapy Pipeline at Key Industry and Investor ConferencesOctober 6, 2025 | msn.comOcugen to Present at Industry and Investor Conferences in October 2025October 2, 2025 | markets.businessinsider.comOcugen to Present at Major Biotechnology Conferences Focused on Advancements in Gene Therapies for Blindness DiseasesOctober 2, 2025 | quiverquant.comQSee More Ocugen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Ocugen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ocugen and other key companies, straight to your email. Email Address About OcugenOcugen (NASDAQ:OCGN) Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline. In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders. Lead candidates include OCU400 for retinitis pigmentosa and OCU410 for wet age-related macular degeneration, each engineered to deliver functional genetic material to retinal cells. The company’s approach is rooted in adeno-associated viral (AAV) vector technology, which has the potential to enable single-administration treatments and durable therapeutic benefits for patients facing progressive vision loss. On the vaccine front, Ocugen entered into a collaboration with India-based Bharat Biotech in mid-2020 to co-develop and commercialize the COVID-19 vaccine Covaxin in the United States and Canada. This partnership illustrates Ocugen’s ability to partner with established developers to bring critical vaccine candidates into North American regulatory pathways. The company is also exploring additional vaccine opportunities that may leverage its manufacturing and distribution networks. Founded in 2014, Ocugen is led by President and Chief Executive Officer Dr. Shankar Musunuri, who co-founded the company with the goal of addressing conditions with limited or no treatment options. Under his leadership and that of an experienced management team, Ocugen continues to advance its pipeline through clinical trials and regulatory interactions, with a mission to deliver innovative therapies for patients worldwide.View Ocugen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Freeport-McMoRan Posts Strong Earnings Despite Indonesia ShutdownTesla’s Earnings Review: Does the Juice Justify the Squeeze?Fal.Con Europe Could Be CrowdStrike’s Early Earnings CatalystLogitech Eyes Breakout Before Earnings—Citigroup Sees 30% UpsideLouis Vuitton Earnings Show Luxury Bull Market Isn’t Done YetGoldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings Upcoming Earnings Cadence Design Systems (10/27/2025)NXP Semiconductors (10/27/2025)Welltower (10/27/2025)Waste Management (10/27/2025)Booking (10/28/2025)Electronic Arts (10/28/2025)Mondelez International (10/28/2025)PayPal (10/28/2025)Regeneron Pharmaceuticals (10/28/2025)American Tower (10/28/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
